Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy

Journal of Clinical Densitometry

Volumn 13, Issue 4, 2010, Pages 441-450

  Paggiosi, Margaret A ^a   Clowes, Jackie A ^b   Finigan, Judith ^a   Naylor, Kim E ^a   Peel, Nicola F A ^a   Eastell, Richard ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Bone mineral density; Magnitude of change; Offset effect; Quantitative ultrasound; Raloxifene

Indexed keywords

CALCIUM CARBONATE; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; MONITORING; OSTEOPENIA; PATIENT COMPLIANCE; PERFORMANCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ULTRASOUND; RANDOMIZED CONTROLLED TRIAL; ULTRASOUND;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 77958508136     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.06.006     Document Type: Article

References (19)

1. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2009, 12(3):157-170.
2. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
3. Morii H., Ohashi Y., Taketani Y., et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 2003, 14(10):793-800.
4. Hans D., Arlot M.E., Schott A.M., et al. Do ultrasound measurements on the os calcis reflect more the bone microarchitecture than the bone mass? A two-dimensional histomorphometric study. Bone 1995, 16(3):295-300.
5. Barkmann R., Lusse S., Stampa B., Sakata S., Heller M., Gluer C.C. Assessment of the geometry of human finger phalanges using quantitative ultrasound in vivo. Osteoporosis Int 2000, 11(9):745-755.
6. Gonnelli S., Cepollaro C., Montagnani A., et al. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int 2002, 13(5):415-421.
7. Ingle B.M., Machado A.B., Pereda C.A., Eastell R. Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. J Clin Densitom 2005, 8(3):278-286.
8. Agostinelli D., de Terlizzi F. QUS in monitoring raloxifene and estrogen-progestogens: a 4-year longitudinal study. Ultrasound Med Biol 2007, 33(8):1184-1190.
9. Krieg M.-A., Barkmann R., Gonnelli S., et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11(1):163-187.
10. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89(3):1117-1123.
11. Clowes J.A., Peel N.F.A., Blumsohn A., et al. Can multiple measurements or pooled measurements reduce within-subject variability?. J Bone Miner Res 2004, 19(Suppl 1):M136.
12. Naylor K.E., Clowes J.A., Finigan J., et al. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 2010, 46(3):592-597.
13. Langton C.M., Palmer S.B., Porter R.W. The measurement of broadband ultrasonic attenuation in cancellous bone. Eng Med 1984, 13(2):89-91.
14. Njeh C.F., Boivin C.M., Langton C.M. The role of ultrasound in the assessment of osteoporosis: a review. Osteoporos Int 1997, 7(1):7-22.
15. Zagzebski J.A., Rossman P.J., Mesina C., Mazess R.B., Madsen E.L. Ultrasound transmission measurements through the os calcis. Calcif Tissue Int 1991, 49(2):107-111.
16. Mele R., Masci G., Ventura V., et al. Three-year longitudinal study with quantitative ultrasound at the hand phalanx in a female population. Osteoporos Int 1997, 7(6):550-557.
17. Baim S., Wilson C.R., Lewiecki E.M., et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005, 8(4):371-378.
18. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Group Study. N Engl J Med 1995, 333(22):1437-1443.
19. Lenchik L., Kiebzak G.M., Blunt B.A. What is the role of serial bone mineral density measurements in patient management?. J Clin Densitom 2002, 5(Suppl):S29-S38.